In this article, we will list the 5 High Growth Stocks to Buy Right Now. Please visit 10 High Growth Stocks to Buy Right Now to see the extended list and the methodology behind it.
5. Neurocrine Biosciences Inc. (NASDAQ:NBIX)
Number of Hedge Fund Holders: 53
Neurocrine Biosciences Inc. (NASDAQ:NBIX) is one of the high growth stocks to buy right now. On June 15, Neurocrine Biosciences presented findings from the first retrospective case series evaluating CRENESSITY (crinecerfont) in patients with classic congenital adrenal hyperplasia/CAH due to 11β-hydroxylase deficiency (11β-OHD). This study provides preliminary evidence for a rare CAH subtype previously unexamined in clinical trials, showing that the treatment significantly reduces adrenal hormone and steroid precursor levels.
In the study of 15 pediatric and adult patients, the initiation of CRENESSITY led to median reductions of over 90% in 11-deoxycortisol and 11-deoxycorticosterone. Furthermore, 14 out of 15 patients were able to decrease their total daily glucocorticoid dose, and some patients receiving antihypertensive medication were able to reduce or discontinue their use of those drugs, reflecting improved hormonal and clinical control.
These findings offer foundational clinical insights into the potential for CRENESSITY to manage the complex hormonal imbalances associated with 11β-OHD. By targeting ACTH, the treatment appears to help normalize hormone levels that contribute to hypertension and other complications, supporting the company’s commitment to advancing care for all patients across the spectrum of classic CAH.
Neurocrine Biosciences Inc. (NASDAQ:NBIX) is a biopharmaceutical company with a focus on neuroscience. It is involved in the R&D, sale, and commercialization of pharmaceuticals that treat neuroendocrine, neurological, and neuropsychiatric disorders.
4. Viking Holdings Ltd. (NYSE:VIK)
Number of Hedge Fund Holders: 55
Viking Holdings Ltd. (NYSE:VIK) is one of the high growth stocks to buy right now. On June 11, Viking announced the delivery of two new river ships, the Viking Annar and the Viking Fjolvar, both constructed at the Meyer Neptun Werft shipyard in Germany. The Viking Annar is designed for itineraries on the Rhine, Main, and Danube rivers, while the Viking Fjolvar will serve routes on the Seine River, including exclusive docking access in the heart of Paris.
These additions expand Viking’s fleet of award-winning longships, which are noted for their Scandinavian design, patented square-bow engineering, and innovative indoor/outdoor spaces. The new vessels offer modern, comfortable accommodations for guests, with the Viking Annar hosting 190 passengers and the Viking Fjolvar hosting 168.
This delivery aligns with Viking Holdings Ltd.’s (NYSE:VIK) long-term growth strategy to remain a leader in experiential travel. The company has a robust expansion plan that includes the delivery of 22 additional river ships by 2028, nine ocean ships by 2031, and 2 expedition ships by 2031, reinforcing its commitment to scaling its global river and maritime operations.
Viking Holdings Ltd. (NYSE:VIK) engages in passenger shipping and other forms of passenger transport in North America, the UK, and internationally. It operates through the River & Ocean segments.
3. Comfort Systems USA Inc. (NYSE:FIX)
Number of Hedge Fund Holders: 80
Comfort Systems USA Inc. (NYSE:FIX) is one of the high growth stocks to buy right now. On June 22, Comfort Systems announced leadership transitions effective July 1, aimed at positioning the company for long-term growth. Craig Sasser, currently Regional Vice President of the Atlantic Region, will be promoted to Chief Operating Officer, while Trent T. McKenna will continue in his role as President.
The company also announced that Briston Blair will transition from his current position as Senior Vice President of Innovation & Strategy to Chief Strategy & Innovation Officer. CEO Brian Lane highlighted that these appointments reflect the company’s focus on utilizing proven leadership and strategic innovation to create ongoing value for stakeholders.
Both executives bring significant experience to their new roles. Mr. Sasser, a veteran with over four decades of industry experience, joined Comfort Systems USA Inc. (NYSE:FIX) in 2018, while Mr. Blair has been instrumental in leading the company’s growth and innovation initiatives since 2022.
Comfort Systems USA Inc. (NYSE:FIX) provides mechanical and electrical installation, renovation, maintenance, repair, and replacement services across the US.
2. Eli Lilly and Company (NYSE:LLY)
Number of Hedge Fund Holders: 132
Eli Lilly and Company (NYSE:LLY) is one of the high growth stocks to buy right now. On June 14, Eli Lilly announced positive results from the Phase 3 BRUIN CLL-322 clinical trial, which evaluated the addition of Jaypirca (pirtobrutinib) to a time-limited venetoclax and rituximab regimen for patients with relapsed or refractory chronic lymphocytic leukemia/CLL or small lymphocytic lymphoma/SLL. The study met its primary endpoint, showing that the pirtobrutinib combination reduced the risk of disease progression or death by 45% compared to the control arm of venetoclax and rituximab alone.
The trial enrolled 639 patients, nearly 80% of whom had been previously treated with a covalent BTK inhibitor, making the findings highly relevant to current clinical practices. At a median follow-up of 27.3 months, the median progression-free survival/PFS in the pirtobrutinib arm had not been reached, compared to 39.7 months in the control arm. These benefits were consistent across various high-risk patient subgroups, and the pirtobrutinib combination also showed a significant advantage in the time to next treatment.
The safety profile of the regimen was consistent with the known profiles of the individual medicines, with minimal additive toxicity observed when adding pirtobrutinib. Discontinuation rates due to treatment-related adverse events were similar between the two study arms. Based on these findings, Eli Lilly and Company (NYSE:LLY) plans to submit the data to global regulatory authorities with the goal of expanding the use of Jaypirca as a potential new standard of care in previously treated CLL/SLL populations.
Eli Lilly and Company (NYSE:LLY) is a healthcare company that develops human pharmaceutical products, including cardiometabolic health, oncology, and immunology products.
1. NVIDIA Corporation (NASDAQ:NVDA)
Number of Hedge Fund Holders: 275
NVIDIA Corporation (NASDAQ:NVDA) is one of the high growth stocks to buy right now. On June 23, NVIDIA introduced the BioNeMo Agent Toolkit, a new software suite providing domain-specific tools designed to enable AI agents to accelerate scientific discovery in life sciences. By integrating over a decade of NVIDIA’s libraries and models, the toolkit allows AI systems to perform complex tasks such as protein design, molecular docking, and genomic analysis, acting as a “scientific toolbox” for research-oriented AI.
The toolkit enables agents to gather evidence, reason through findings, and execute computational experiments, essentially providing them with the expertise of a research assistant combined with the speed of a supercomputer. Powered by NVIDIA’s NIM microservices and other core technologies, the platform is already being adopted by over 50 organizations (including major pharmaceutical companies and research institutions) to streamline workflows in drug discovery and biotechnology.
By allowing AI agents to understand and execute scientific processes autonomously, NVIDIA Corporation (NASDAQ:NVDA) aims to shift the paradigm of research toward faster, iterative design cycles. Collaborations with leaders like the University of Washington’s Institute for Protein Design have already demonstrated significant performance gains, highlighting the toolkit’s potential to dramatically reduce the time and cost required to solve complex problems in biology, chemistry, and medicine.
NVIDIA Corporation (NASDAQ:NVDA) is a fabless semiconductor and AI computing company that designs GPUs, AI accelerators, Application Programming Interfaces (APIs), and system-on-a-chip units. Through its CUDA ecosystem, the company enables industries ranging from autonomous vehicles to scientific research by advancing AI, accelerated computing, and data center infrastructure.
While we acknowledge the potential of NVDA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NVDA and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 10 Best Growth Stocks Under $30 to Buy Now and 12 Best Growth Stocks Trading in Oversold Territory.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
